Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00864175
What this trial is testing

Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Incyte Corporation 68
Testing effectiveness (Phase 2)WithdrawnNCT03377101
What this trial is testing

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeProgesterone Receptor Positive+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT00095862
What this trial is testing

Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers

Who this might be right for
Breast CancerUnspecified Adult Solid Tumor, Protocol Specific
Wiseman Research Initiatives LLC 24
Not applicableStudy completedNCT01899079
What this trial is testing

A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay

Who this might be right for
Breast Cancer
NanoString Technologies, Inc. 217
Not applicableStudy completedNCT05173103
What this trial is testing

Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone Receptor Positive Breast CarcinomaHER2-negative Breast Cancer
University of Milano Bicocca 254
Testing effectiveness (Phase 2)Study completedNCT03747042
What this trial is testing

Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

Who this might be right for
Breast Cancer Female
University of Texas Southwestern Medical Center 61
Testing effectiveness (Phase 2)Active Not RecruitingNCT04567420
What this trial is testing

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Who this might be right for
Breast Cancer
Criterium, Inc. 70
Large-scale testing (Phase 3)Looking for participantsNCT07003074
What this trial is testing

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 642
Early research (Phase 1)Study completedNCT02248090
What this trial is testing

AZD9496 First Time in Patients Ascending Dose Study

Who this might be right for
ER+ HER2- Advanced Breast Cancer
AstraZeneca 45
Not applicableLooking for participantsNCT07583485
What this trial is testing

GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting

Who this might be right for
Breast Cancer
Fondazione Oncotech 300
Testing effectiveness (Phase 2)UnknownNCT00250874
What this trial is testing

Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Zeneus Pharma 45
Testing effectiveness (Phase 2)Study completedNCT02871791
What this trial is testing

Palbociclib With Everolimus + Exemestane In BC

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor (HR)-Positive Breast Cancer
Dana-Farber Cancer Institute 41
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07136974
What this trial is testing

Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.

Who this might be right for
Breast CancerHER2 + Breast Cancer
Henan Cancer Hospital 280
Early research (Phase 1)Study completedNCT02562378
What this trial is testing

T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
MedSIR 15
Not applicableWithdrawnNCT01159236
What this trial is testing

Molecular Triaging of Newly Diagnosed Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT04113863
What this trial is testing

Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer

Who this might be right for
Breast Neoplasm Female
Mario Negri Institute for Pharmacological Research 76
Not applicableStudy completedNCT00918892
What this trial is testing

Assessment of Candidate Protein Expression in Breast Cancer Specimens

Who this might be right for
Breast Cancer
Case Comprehensive Cancer Center 460
Large-scale testing (Phase 3)Study completedNCT00391092
What this trial is testing

Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Hoffmann-La Roche 424
Large-scale testing (Phase 3)Study completedNCT01702571
What this trial is testing

Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Who this might be right for
Breast Cancer
Hoffmann-La Roche 2,185
Not applicableLooking for participantsNCT06272799
What this trial is testing

Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.

Who this might be right for
Breast Cancer
Regina Elena Cancer Institute 160
Next Page